These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38626563)

  • 21. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
    J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
    Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
    J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 25. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
    Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
    Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
    CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
    Lucchese AC; Sarin LM; Magalhães EJM; Del Sant LC; B Puertas C; Tuena MA; Nakahira C; Fava VA; Delfino R; Surjan J; Steiglich MS; Barbosa M; Abdo G; Cohrs FM; Liberatori A; Del Porto JA; Lacerda AL; B Andreoli S
    J Psychopharmacol; 2021 Feb; 35(2):142-149. PubMed ID: 33427015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
    Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.
    Sharman Moser S; Chodick G; Gelerstein S; Barit Ben David N; Shalev V; Stein-Reisner O
    BMC Psychiatry; 2022 Aug; 22(1):541. PubMed ID: 35948895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
    Vázquez GH; Bahji A; Undurraga J; Tondo L; Baldessarini RJ
    J Psychopharmacol; 2021 Aug; 35(8):890-900. PubMed ID: 34238049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature].
    Mungo A; Hein M
    Encephale; 2022 Aug; 48(4):455-461. PubMed ID: 35221019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M; Bartova L; Kasper S
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):440-445. PubMed ID: 32570275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
    Sanders B; Brula AQ
    J Psychiatr Res; 2021 May; 137():29-35. PubMed ID: 33647726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
    Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC
    J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609
    [No Abstract]   [Full Text] [Related]  

  • 38. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
    Kasper S; Cubała WJ; Fagiolini A; Ramos-Quiroga JA; Souery D; Young AH
    World J Biol Psychiatry; 2021 Jul; 22(6):468-482. PubMed ID: 33138665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
    Singh B; Vande Voort JL; Pazdernik VK; Frye MA; Kung S
    J Affect Disord; 2024 Apr; 351():534-540. PubMed ID: 38302067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.
    Canuso CM; Ionescu DF; Li X; Qiu X; Lane R; Turkoz I; Nash AI; Lopena TJ; Fu DJ
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):516-524. PubMed ID: 34412104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.